A Multi-center, Randomized, Double Blind, Parallel-arm, Placebo Controlled Trial of Mepolizumab for Treatment of Adults and Adolescents With Active Eosinophilic Esophagitis and Dysphagia-predominant Symptoms
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Mepolizumab (Primary)
- Indications Deglutition disorders; Eosinophilic oesophagitis
- Focus Therapeutic Use
- 11 Nov 2019 Planned End Date changed from 1 Jun 2021 to 1 Dec 2020.
- 07 Feb 2019 Status changed from not yet recruiting to recruiting.
- 11 Sep 2018 New trial record